案例 Products
产品名称

Colorectal Carcinoma

发布时间 2018-03-02
点击次数 415
  • 基本参数
  • 部件材质
  • 应用概述
  • 相关下载

     With 655,000 deaths worldwide per year, colorectal cancer (CRC) is the second leading cause of cancer-related death in Western society and the incidence and mortality are increasing dramatically in the rest of the world. Approximately 25% of  patients have a family history of CRC, suggesting a genetic contribution, common exposures among family members or a combination of both. Other risk factors for CRC include diet, use of non-steroidal anti-inflammatory drugs (NSAIDs), postmenopausal hormone use, cigarette smoking, colonoscopy with removal of adenomatous polyps and physical activity. Two major molecular events are associated with the disease: chromosomal instability (CIN) is involved in about 85% of CRCs and microsatellite instability (MSI or MIN) in remaining 15%. For example, loss/mutations of APC gene, associated with CIN is one of the early events in the colorectal  tumor progression and predisposition to colorectal tumors.


Colorectal Carcinoma

     Great advances have been made in the treatment and prevention of advanced CRC in the past 20 years. Survival time has increased from 6 months to over 2 years. However, among patients diagnosed with metastatic colorectal cancer (mCRC), the 5-year survival rate is only 8% on average. Effective new drugs to arrest the progression or prevent the occurrence of CRC are very desirable. Great efforts have been paid to investigate the therapeutic effects of novel compounds using different CRCs and treatment strategies in animal models.     


PharmaLegacy Models and Research Tools


CRC models:

     *Human CRC subcutaneous xenograft models in nude mice (HCT-116, HT-29, COLO205, HCT-15)

     *Human CRC orthotopic implantation models in nude mice

     *Human primary CRC models in nude mice (7 tumors, subcutaneous xenograft or 

      orthotopic model)

     *Luciferase-reporter based CRC imaging model (orthotopic growth and metastasis, HT-29-Luc)

Model characteristics:

     *Metastasis is rare in subcutaneous xenograft tumor models

     *Different tumor lines may respond differently to specific drug treatment

     *Orthotopic tumor models recreate human CRC with a similar microenvironment of CRC growth 

      with both local and remote metastasis

     *Collection of human primary CRC tumors features Asia CRC patients and facilitate the animal 

       based Phase II like studies and translational studies

     *HT-29-Luc tumor model with Luciferase reporter allows real time imaging of the orthotopic 

       tumor growth and metastasis

Tumor biology, biomarkers, and molecular pharmacology:

     *Tumor volume/weight, animal body weight and mortality

     *Cytokine/chemokine/biomarker analysis (ELISA, Q-PCR, Western blot)

     *Kinase activity assay and phosphorylation analysis

     *Hematology

     Colorectal Carcinoma

     Colorectal Carcinoma

Products / 相关产品
2018 - 03 - 05
Immuno-Oncology IntroductionImmuno-therapy has now been representing a significant paradigm shift in cancer treatment after the promising clinical data from the immune-checkpoint m...
2018 - 03 - 02
Gastric Carcinoma     Introduction     Gastric carcinoma remains a common disease with a dismal prognosis. It represents the fourth most frequent mali...
2018 - 03 - 02
With 655,000 deaths worldwide per year, colorectal cancer (CRC) is the second leading cause of cancer-related death in Western society and the incidence and mortality are increasing dramatically in th...
Copyright ©2013 - 2018 
澎立生物医药技术(上海)有限公司
X
1

QQ设置

3

SKYPE 设置

4

阿里旺旺设置

5

电话号码管理

  • +86-21-6100-2270
6

二维码管理

等待加载动态数据...

等待加载动态数据...

回到顶部
展开